Galectin Therapeutics Stock Performance
| GALT Stock | USD 1.25 0.02 1.63% |
The company retains a Market Volatility (i.e., Beta) of 0.72, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Galectin Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Galectin Therapeutics is expected to be smaller as well. At this point, Galectin Therapeutics has a negative expected return of -0.68%. Please make sure to check out Galectin Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Galectin Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Galectin Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:6 | Last Split Date 2012-03-23 |
1 | Galectin Therapeutics GAAP EPS of -0.18 | 11/14/2024 |
2 | Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases 2024 Liver Meeting | 11/18/2024 |
3 | StockNews.com Upgrades Galectin Therapeutics to Hold - MarketBeat | 11/20/2024 |
4 | Acquisition by Joel Lewis of 11606 shares of Galectin Therapeutics at 1.66 subject to Rule 16b-3 | 11/29/2024 |
5 | Tenax appoints new interim CFO in executive shuffle | 12/05/2024 |
6 | Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH | 12/20/2024 |
7 | Acquisition by Callicutt Jack W of 40000 shares of Galectin Therapeutics subject to Rule 16b-3 | 12/23/2024 |
8 | Acquisition by Freeman Kevin D of 10000 shares of Galectin Therapeutics at 0.8134 subject to Rule 16b-3 | 12/24/2024 |
9 | Hedge Fund and Insider Trading News Warren Buffett, Ray Dalio, Stanley Druckenmiller, Liberty Latin America , Galectin Therapeutics Inc , and More | 12/26/2024 |
10 | Acquisition by Shlevin Harold H. of 6500 shares of Galectin Therapeutics at 1.16 subject to Rule 16b-3 | 12/30/2024 |
11 | Galectin Therapeutics Highlights Promising NAVIGATE Trial Results - TipRanks | 01/13/2025 |
12 | Acquisition by Omenn Gilbert S of 60000 shares of Galectin Therapeutics at 1.23 subject to Rule 16b-3 | 01/23/2025 |
13 | Acquisition by Callicutt Jack W of 60000 shares of Galectin Therapeutics subject to Rule 16b-3 | 01/28/2025 |
| Begin Period Cash Flow | 18.6 M |
Galectin |
Galectin Therapeutics Relative Risk vs. Return Landscape
If you would invest 253.00 in Galectin Therapeutics on November 3, 2024 and sell it today you would lose (128.00) from holding Galectin Therapeutics or give up 50.59% of portfolio value over 90 days. Galectin Therapeutics is currently does not generate positive expected returns and assumes 9.1335% risk (volatility on return distribution) over the 90 days horizon. In different words, 81% of stocks are less volatile than Galectin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galectin Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galectin Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Galectin Therapeutics, and traders can use it to determine the average amount a Galectin Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0744
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GALT |
Estimated Market Risk
| 9.13 actual daily | 81 81% of assets are less volatile |
Expected Return
| -0.68 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Galectin Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galectin Therapeutics by adding Galectin Therapeutics to a well-diversified portfolio.
Galectin Therapeutics Fundamentals Growth
Galectin Stock prices reflect investors' perceptions of the future prospects and financial health of Galectin Therapeutics, and Galectin Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galectin Stock performance.
| Return On Equity | -37.28 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | 156.95 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) | ||||
| Net Income | (41.07 M) | ||||
| Cash And Equivalents | 15.83 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 71.81 M | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.01) X | ||||
| Cash Flow From Operations | (32.97 M) | ||||
| Earnings Per Share | (0.73) X | ||||
| Market Capitalization | 78.45 M | ||||
| Total Asset | 28.2 M | ||||
| Retained Earnings | (354.37 M) | ||||
| Working Capital | 12.03 M | ||||
| Current Asset | 26.4 M | ||||
| Current Liabilities | 1.36 M | ||||
About Galectin Therapeutics Performance
Assessing Galectin Therapeutics' fundamental ratios provides investors with valuable insights into Galectin Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Galectin Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (3.50) | (3.32) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | 0.78 | 0.74 |
Things to note about Galectin Therapeutics performance evaluation
Checking the ongoing alerts about Galectin Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galectin Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galectin Therapeutics generated a negative expected return over the last 90 days | |
| Galectin Therapeutics has high historical volatility and very poor performance | |
| Galectin Therapeutics may become a speculative penny stock | |
| Galectin Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Galectin Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Callicutt Jack W of 60000 shares of Galectin Therapeutics subject to Rule 16b-3 |
- Analyzing Galectin Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galectin Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Galectin Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galectin Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galectin Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galectin Therapeutics' stock. These opinions can provide insight into Galectin Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.